COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
30/07/2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior [...]
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
30/07/2026
Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), [...]
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
30/07/2026
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 Launched Expanded Access Program ( [...]
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
30/07/2026
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following [...]
NewGen Provides Update on K25.ai Investment and Strengthened Financial Position
30/07/2026
NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen’s agreed 13% stake in K25.ai is now valued at approximately US$ [...]
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
30/07/2026
Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder [...]
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
30/07/2026
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Relation unveils MORGAN, the next-generation model of cellular biology
30/07/2026
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship cellular foundation model designed to transform how new biology [...]
Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
30/07/2026
London, UK – 30 July 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Relation Announces Expanded Collaboration with GSK
30/07/2026
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- [...]
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
30/07/2026
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its exclusive U.S. commercialization option for Tadekinig alfa after AB2 Bio’s [...]
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine
30/07/2026
Proposed expansion in the Cluj-Napoca region intended to strengthen PET imaging supply and support continued development of regional nuclear medicine services BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Curium™ announced [...]
Sugar Reset Drops Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026
30/07/2026
Sugar Reset Drops' Chromium Dose, Grapefruit and Licorice Interaction Details, and 20% Refund Fee Explained Largo, FL, July 30, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and Drug [...]
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
30/07/2026
Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER 1 and business earnings per share (EPS) 2 of €2.09 Pharma launches sales increased [...]
Communiqué de presse : T2 2026 : croissance à deux chiffres du chiffre d’affaires et forte progression du BNPA ; révision à la hausse des perspectives 2026
30/07/2026
T2 2026 : croissance à deux chiffres du chiffre d’affaires et forte progression du BNPA ; révision à la hausse des perspectives 2026 Paris, le 30 juillet 2026 Ventes du T2 en progression de 17,8 % à TCC 1 et BNPA 2 des [...]
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
30/07/2026
H1 2026 results with sales growth of 23.5% at CER 1 , or 20.4% as reported, with the portfolio beyond Somatuline ® achieving sales growth of 24.8% 1 and core operating income of €845m, growing by 28.8% as reported, with [...]
Ipsen réalise d’excellents résultats au premier semestre 2026 et relève ses objectifs financiers annuels
30/07/2026
Croissance semestrielle du chiffre d’affaires du Groupe de 23,5 % à taux de change constant 1 (20,4 % en données publiées), tirée par une croissance de 24,8 % des ventes du portefeuille de médicaments hors Somatuline [...]
Regulated information: Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance
30/07/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 July 2026 – 7:00 AM CET Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance Fagron, the leading [...]

Pages